Mazdutide: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •1 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 5 community reports
- •Stacking patterns detailed below
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Regional Availability | Mazdutide (IBI362) was approved in China in 2025 for weight management by Innovent Biologics. Phase 3 trials were primarily conducted in Chinese populations. | Western community members have limited access to mazdutide. Most community discussion comes from Chinese-language forums or from users importing Chinese-approved formulations. A small number of research chemical vendors offer research-grade mazdutide. | high Population-specific clinical data (primarily Chinese participants) may not fully generalize to other populations. Access pathways for Western users carry additional quality and regulatory risks. |
| Dual Agonism Mechanism | Mazdutide is a dual GLP-1/glucagon receptor agonist, similar in concept to survodutide but with different receptor binding ratios and pharmacokinetic properties. | Community interest in mazdutide relates to its glucagon receptor component, which may provide enhanced energy expenditure and liver fat reduction compared to GLP-1-only agonists. Direct community comparison with survodutide is limited. | moderate The dual agonist mechanism is shared with survodutide, but mazdutide has the advantage of being commercially approved (in China), providing more real-world use data. |
Compare these community approaches with published research findings.
Community Protocols
Clinical Trial-Based Protocol
Niche- Route
- Subcutaneous
- Dose
- 3-9 mg
- Frequency
- Once weekly
- Duration
- 24-48 weeks
Based on Phase 3 trial doses (3, 4.5, 6, 9 mg weekly); mazdutide is approved in China but not in the US or EU; community access primarily through Chinese research suppliers
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 5+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Peptides|Mazdutide and dual agonist pipeline discussions(accessed 2026-02-16)
- Reddit r/Semaglutide|Next-generation obesity peptides including mazdutide(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Mazdutide (IBI362). The information below is gathered from Reddit communities and online forums. This is not clinical evidence and should not be used as medical guidance.
Mazdutide has limited Western community adoption due to its approval being restricted to China. Community discussion primarily focuses on clinical trial data analysis and comparisons with other dual or triple agonist peptides in the pipeline.
Regional Context#
Mazdutide was approved in China in 2025 but is not available in the US or EU. This creates a unique community dynamic where most Western discussion is anticipatory or analytical rather than experiential. Community reports from Chinese users are occasionally translated and shared in English-language forums.
Limited Community Use#
Western community access to mazdutide is extremely limited. The few reports that exist come from:
- Users importing from Chinese pharmacies or suppliers
- Research chemical vendor products of uncertain quality
- Clinical trial participants sharing experiences
Important Caveats#
- Mazdutide is not FDA-approved; only approved in China
- Western community access is very limited
- Clinical trial data is primarily from Chinese populations
- Research-grade products from unregulated suppliers carry quality risks
- No established community protocol consensus exists for Western users
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Mazdutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.